Binding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors

Phytomedicine

Volumn 13, Issue SUPPL. 1, 2006, Pages 51-55

  Simmen, U ^a   Kelber, O ^b   Okpanyi, S N ^b   Jaeggi, R ^c   Bueter, B ^c   Weiser, D ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Steigerwald Arzneimittelwerk GmbH   (Germany)

^c VitaPlant AG   (Switzerland)

Author keywords

5 HT4; Angelica archangelica; Carum carvi; Chamomilla recutita; Chelidonium majus; Functional dyspepsia (FD); Glycyrrhiza glabra; Iberis amara; Iberogast; Irritable bowel syndrome (IBS); Melissa officinalis; Mentha piperita; Muscarinic M3; Opioid receptors; Receptor binding; Serotonin 5 HT3; Silybum marianum; STW 5

Indexed keywords

BENZYLISOQUINOLINE DERIVATIVE; BERBERINE DERIVATIVE; CHAMOMILE; HERBACEOUS AGENT; IBEROGAST; MUSCARINIC M3 RECEPTOR ANTAGONIST; OPIATE ANTAGONIST; PLANT MEDICINAL PRODUCT; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; STW 5; UNCLASSIFIED DRUG;

ANGELICA ARCHANGELICA; ANIMAL TISSUE; ARTICLE; CARAWAY; CHELIDONIUM; CONTROLLED STUDY; DILUTION; DRUG BINDING; DRUG INHIBITION; DRUG POTENTIATION; DRUG SELECTIVITY; GLYCYRRHIZA; GLYCYRRHIZA GLABRA; IBERIS AMARA; IC 50; MATRICARIA; MEDICINAL PLANT; MELISSA OFFICINALIS; MENTHA PIPERITA; NONHUMAN; PRIORITY JOURNAL; RAT; SILYBUM MARIANUM;

ANIMALS; BINDING, COMPETITIVE; INTESTINES; PLANT EXTRACTS; RATS; RATS, WISTAR; RECEPTORS, MUSCARINIC; RECEPTORS, OPIOID; RECEPTORS, SEROTONIN;

ANGELICA ARCHANGELICA; CARUM CARVI; CHELIDONIUM; CHELIDONIUM MAJUS; GLYCYRRHIZA GLABRA; IBERIS AMARA; MATRICARIA RECUTITA; MELISSA OFFICINALIS; MENTHA X PIPERITA; SILYBUM MARIANUM;

EID: 33751328340     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2006.03.012     Document Type: Article

References (20)

1. Allescher H. Functional dyspepsia - a multi-causal disease and its therapy. Phytomedicine 13 Suppl. V (2006) 2-11
2. Ammon H.P.T., Kelber O., and Okpanyi S.N. Spasmolytic and tonic effect of Iberogasts (STW 5) in intestinal smooth muscle. Phytomedicine 13 Suppl. V (2006) 67-74
3. Berman S.M., Chang L., Suyenobu B., Derbyshire S.W., Stains J., Fitzgerald L., Mandelkern M., Hamm L., Vogt B., Naliboff B.D., and Mayer E.A. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology 123 (2002) 969-977
4. Callahan M.J. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J. Clin. Gastroenterol. 35 Suppl. (2002) 58-67
5. Chamilleri M. Treating irritable bowel syndrome: overview, perspective and future therapies. Br. J. Pharmacol. 141 (2004) 1237-1248
6. Houghton L.A., Rogers J., Whorwell P.J., Campbell F.C., Williams N.S., and Goka J. Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Aliment Pharmacol. Ther. 11 (1997) 561-568
7. Kamm M.A. The complexity of drug development for irritable bowel syndrome. Aliment Pharmacol. Ther. 16 (2002) 343-351
8. Kelber O., Wittwer, A., Lapke, C., Kroll, U., Weiser, D., Okpanyi, S.N., Heilmann, J., Ex vivo/in vitro absorption of STW 5 (Iberogasts) and its extract components. Phytomedicine 13 (Suppl. V), 107-113.
9. Khayyal M.T., Seif-El-Nasr M., El-Ghazaly M.A., Okpanyi S.N., Kelber O., and Weiser D. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast®) and its components against ulcers and rebound acidity. Phytomedicine 13 Suppl. V (2006) 56-66
10. Michael, S., Kelber, O., Vinson, B., Nieber, K., 2006. Herbal preparations STW 5 and STW 6 inhibit inflammation-mediated motility disorders in the ileum. Gut, in press.
11. Müller M.H., Liu C.-Y., Glatzle J., Weiser D., Kelber O., Enck P., Grundy D., and Kreis M.E. STW 5 (Iberogast) reduces afferent sensitivity in the rat small intestine. Phytomedicine 13 Suppl. V (2006) 100-106
12. Nikolay K. Funktionelle Gastroenteropathien im therapeutischen Blindvergleich von Metoclopramid mit dem Phytopharmakon Iberogast. Gastro-Entero-Hepatologie 2 (1984) 24-28
13. Okpanyi S.N., and Wahl M.A. Gastrointestinal motility modulation with Iberogast. Acta Hortic. 332 (1993) 227-235
14. Prins N.H., Van Haselen J.F., Lefebvre R.A., Briejer M.R., Akkermans L.M., and Schuurkes J.A. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br. J. Pharmacol. 127 (1999) 1431-1437
15. ® on proximal gastric volume, antropyloroduodenal (APD) motility and gastric emptying in healthy men. Neurogastroenterol. Motility, in press.
16. Roesch W., Vinson B., and Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z. Gastroenterol. 40 (2002) 401-408
17. Rösch W., Vinson B., Gundermann K.H., and Holtman G. Clinical efficacy and safety of STW 5 - a review. Phytomedicine 13 Suppl. V (2006) 114-121
18. Saller R., Pfister-Hotz G., Iten F., Melzer J., and Reichling J. Iberogast: Eine moderne phytotherapeutische Arzneimittelkombination zur behandlung funktioneller Erkrankungen des Magen-Darm-Trakts (Dyspepsie, Colon irritabile) - von der Pflanzenheilkunde zur "Evidence Based Phytotherapy". Eine systematische Übersicht. Forsch Komlementärmed Klass Naturheilk 9 Suppl. 1 (2002) 1-20
19. Schemann M., Hohenester B., and Rühl A. Region-specific effects of STW 5 and its components in gastric fundus/corpus and antrum. Phytomedicine 13 Suppl. V (2006) 90-99
20. Stanghellini V., De Ponti F., De Giorgio R., Barbara G., Tosetti C., and Corinaldesi R. New developments in the treatment of functional dyspepsia. Drugs 63 (2003) 869-892